LifeStance Health Group, Inc. Q4 FY2025 earnings call

2025 was an exceptional year with robust organic revenue and visit growth. Clinician base expanded by 9% and productivity improved by 7% in the second half. Initiatives such as process improvements in clinician scheduling, a cash incentive program for clinicians, expanded patient access, and enhanced patient engagement were implemented. Technology played a role with digital and AI solutions in patient access, clinician experience, and operational efficiency. In 2026, the focus is on EHR transition to a best-in-class vendor, continuing technology enablers with AI and digital tools, attracting new patients and improving conversion, and investments in provider and partner referrals.

In the fourth quarter, revenue grew 17% year over year to $382,000,000, with visit volumes of 2,400,000 increasing 18%. Visits per average clinician increased 7% year over year. Full-year revenue was $1,424,000,000, up 14% year over year. Center margin in the quarter was $126,000,000, increasing 15% year over year and 33% of revenue. Full-year center margin was $461,000,000, growing 15%. Adjusted EBITDA in the quarter was $49,000,000, up 49% year over year, with a 12.8% percentage of revenue, the highest as a public company. Full-year adjusted EBITDA was $158,000,000, up 32% year over year, with margins increasing 150 basis points to 11.1%.

For 2026, full-year revenue is expected to be $1.615 billion to $1.655 billion, center margin $526,000,000 to $550,000,000, and adjusted EBITDA $185,000,000 to $205,000,000. The first quarter revenue is expected to be $380,000,000 to $400,000,000, center margin $118,000,000 to $132,000,000, and adjusted EBITDA $39,000,000 to $45,000,000. Expect to open 20 - 30 new centers in 2026. EHR implementation in 2026 will have a cash use of $20,000,000 to $30,000,000. Beyond 2026, expect mid-teens revenue growth, expand operating leverage in G&A, and reach mid-teens adjusted EBITDA margins by 2028.

Q: Echoing Ken's comments, nice to see execution and strategy, can you talk about productivity inflection and impact on business?

A: Productivity initiatives like phone scheduling for new patients, cash incentive program for clinicians are durable, guiding to 15% revenue growth in 2026 with low double-digit visit growth from net clinician adds and low - to mid-single-digit revenue per visit growth from payer rate increases.

Q: When thinking about path to 15% EBITDA margin and technology investments, how are you looking at ROI payback?

A: Very disciplined in approach to technological solutions, looking at return profile of investment to ensure it pencils out for operating leveraging.

Q: Follow up on visits per clinician up 7% and how digital and AI play into it?

A: Two aspects, increasing clinician capacity and flow of new patients, with AI tools improving conversion rate of phone calls to booked appointments and new care matching algorithm improving conversion and therapeutic alliance.

Q: Follow up on payer rates, where are we on cleaning up managed care relationships and line of sight to low - to mid-single-digit payer rate increases?

A: Pretty much complete on cleaning up payer contracts, having constructive conversations with payers, using annual rate discussions and sometimes multiyear arrangements, feeling good about low - to mid-single-digit payer rate increases in coming years.

Q: Comment about moderating net adds in quarter and efficiency, does that mean measured approach to ensure efficiency and onboarding, backlog, M&A, and buyback?

A: Intentional balance between adding new clinicians and using existing clinicians' capacity for better satisfaction and efficiency, no material M&A in 2026 guidance, active pipeline but disciplined, announced share repurchase program.

Q: Question about 2026 guide and EHR implementation, cost side thinking?

A: EHR implementation cash use $20,000,000 to $30,000,000, most costs adjusted through EBITDA or capitalized, G&A growth rate in 2025 unnaturally low, 2026 guide G&A step-up due to leveraging and ensuring ROI pencils out.

Q: Level-set on KPIs or things for organic growth vs M&A opportunities?

A: Disciplined on financial metrics like multiples on EBITDA, down-market opportunities attractive for geographic expansion, not doing small tuck-ins in existing presence.

Q: Question on EMR, who we are using, capabilities, and payer relationships being price taker or collaborative?

A: Completed EHR discovery, decided on new vendor, new EHR unlocks clinical and operational excellence, workflows, patient experience. Payer relationships have constructive conversations, tension normal, payers under pressure for access leading to constructive dialogues.

Q: Question on 20 - 30 new center adds in 2026, margin cadence and competitive landscape?

A: New centers come on with lower margin profile, fully contemplated in guidance, return profile quick. Competitive landscape is competitive for clinicians, local conversation, no national competitor flagged.

Q: Question on visits per clinician sequentially into 2026, move into 1Q from 4Q level?

A: Revenue step-up from Q4 to Q1 is $8,000,000, 17% year over year, driven by net clinician adds and rate.

Q: Question on free cash flow, de novos in 2025, free cash flow in 2026?

A: De novos timing relatively minor, free cash flow positive in 2025, expect positive again in 2026.

Q: Question on technology driving savings, proportion of cost base addressable and dropping out?

A: Center margin expected to expand from low-thirties to mid-thirties, part from leveraging occupancy cost and G&A line, long-term guidance for mid-teens EBITDA by 2028, confident in ability to implement technology for lower expense base.